RTC
MDGL icon

Riverview Trust Company’s Madrigal Pharmaceuticals MDGL Stock Holding History

Riverview Trust Company’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-2
Closed -$617 – 741
2024
Q4 		$617 Buy
+2
New +$563 ﹤0.01% 738

Other funds holding MDGL

Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Riverview Trust Company's MDGL Position: Q1 2025 in Review

Riverview Trust Company sold out of Madrigal Pharmaceuticals (MDGL) in Q1 2025, closing a stake of 2 shares — an estimated $617 sold.

Riverview Trust Company first reported a position in MDGL in Q4 2024 and held it in 1 quarter. The position peaked at $617 in Q4 2024. 321 funds tracked by Wall St. Rank hold MDGL as of Q1 2025.

  • Riverview Trust Company reported no remaining Madrigal Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Riverview Trust Company sold 2 Madrigal Pharmaceuticals shares in Q1 2025, an estimated $617.
  • Riverview Trust Company first reported a position in Madrigal Pharmaceuticals in Q4 2024 and held it in 1 quarter.
  • Riverview Trust Company's Madrigal Pharmaceuticals position peaked at $617 in Q4 2024.
  • 321 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q1 2025.

Based on Riverview Trust Company's 13F filing for Q1 2025, filed 11 Apr 2025.